Physician profile
Christopher A Smith
NPI 1679675995
$622,425.63
in general payments reported to CMS, 2019-2025
41 companies · $112K in 2025
The $112K reported for 2025 was more than what 97% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $35K · 2021: $51K · 2022: $104K · 2023: $108K · 2024: $125K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $284K · Travel and Lodging: $23K · Consulting Fee: $20K · Food and Beverage: $18K · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,747.50 |
| Travel and Lodging | $22,747.48 |
| Consulting Fee | $20,318.74 |
| Food and Beverage | $17,811.12 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $299,701.40 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $135,191.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $81,494.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $37,024.08 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $20,284.90 | 2019-2025 | Joenja, Ruconest |
| Amgen INC. | $12,142.54 | 2021-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $8,880.23 | 2019-2025 | Xolair |
| Genentech, INC. | $6,792.33 | 2019-2022 | |
| Shire North American Group INC | $5,603.82 | 2019 | |
| Merck Sharp & Dohme LLC | $3,271.61 | 2019-2023 | |
| Grifols USA, LLC | $3,167.75 | 2019-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $1,939.18 | 2019-2025 | |
| Pfizer INC. | $1,355.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,245.16 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.75 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $543.05 | 2019-2025 | |
| Csl Behring | $497.83 | 2019-2025 | Hizentra, Haegarda |
| Biocryst US Sales Co., LLC | $432.22 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $405.63 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $326.72 | 2024-2025 | Dupixent |
| Octapharma USA, INC. | $295.27 | 2022-2025 | Cutaquig, Panzyga |
| Alk-Abello, INC | $196.72 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Abbvie INC. | $183.98 | 2022-2025 | Rinvoq |
| Blueprint Medicines Corporation | $175.26 | 2023-2025 | Ayvakit |
| Aimmune Therapeutics, INC. | $148.74 | 2020-2021 | |
| Adma Biomanufacturing LLC | $129.40 | 2022-2025 | |
| Kaleo, INC. | $67.50 | 2020-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $64.33 | 2025 | Neffy |
| Lilly USA, LLC | $50.82 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $45.10 | 2021-2022 | |
| Emd Serono, INC. | $26.34 | 2025 | |
| Gc Biopharma USA, INC. | $21.37 | 2024 | Alyglo |
| Incyte Corporation | $17.64 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Galderma Laboratories, L.P. | $14.93 | 2025 | Nemluvio |
| Bio Products Laboratory USA, INC. | $14.22 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.